Once I got the hang of administering subcutaneous immunoglobulin, my life was so much easier, as I no longer had to undergo monthly IV infusions for my cancer-related compromised immune system. After ...

In this exclusive MedPage Today video, Jorge Nieva, MD, of the Keck School of Medicine at the University of Southern California in Los Angeles, discusses the growing trend of subcutaneous formulations ...

Subcutaneous nivolumab injection marks a significant advancement in cancer therapy, offering faster administration than traditional intravenous methods. The shift to subcutaneous delivery could lead ...

Please provide your email address to receive an email when new articles are posted on . In this video, Allyson Pishko, MD, MSCE, highlighted two studies from ASH Annual Meeting and Exposition that ...

Please provide your email address to receive an email when new articles are posted on . Despite the benefits and accessibility of administering cancer medications and fluids subcutaneously vs.

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

Roche’s Lunsumio may be the first CD20xCD3 T-cell engager approved by the FDA, but intravenous administration puts the drug at a disadvantage to AbbVie and Genmab’s subcutaneously injected Epkinly.

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Bristol Myers Squibb is offering a detailed look at pivotal data showing that an under-the-skin version of its PD-1 inhibitor Opdivo works as well as the original intravenous formulation in kidney ...